P2.01-22 ORCHARD: A Phase II Platform Study in Patients with Advanced NSCLC Who Have Progressed on First-Line Osimertinib Therapy
Helena A. Yu(Memorial Sloan Kettering Cancer Center), Jonathan W. Riess(University of California Davis Medical Center), Gargi Patel(AstraZeneca (United Kingdom)), B. Kirova, Sarah B. Goldberg(Yale University), P. Szekeres(AstraZeneca (Netherlands)), Peter J. Smith, Ilhem Mensi(AstraZeneca (United Kingdom)), X. Li-Sucholeicki(AstraZeneca (United States)), Juliann Chmielecki(Memorial Sloan Kettering Cancer Center), Zofia Piotrowska(Global Cancer Institute), Philip J. Jewsbury, Gail Doughton(AstraZeneca (United Kingdom)), Xiuning Le(The University of Texas MD Anderson Cancer Center)
Cited by 26
Related Papers
Comprehensive molecular profiling of lung adenocarcinoma
|Nature|2014|5.9k
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k
<i>EGFR</i> Mutations and <i>ALK</i> Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis
|Clinical Cancer Research|2016|1.2k
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%
|Journal of Clinical Oncology|2021|1.1k
Tepotinib in Non–Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping Mutations
|New England Journal of Medicine|2020|879